MedTrace Logo

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

NCT00104949 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-06-24

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Trastuzumab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well trastuzumab works in treating patients with locally advanced or metastatic synovial sarcoma.

Conditions

  • Sarcoma

Interventions

BIOLOGICAL

trastuzumab

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Ernest C. Borden, MD · The Cleveland Clinic

  • Rashmi Chugh, MD · University of Michigan Rogel Cancer Center

  • George D. Demetri, MD · Dana-Farber Cancer Institute

  • Margaret von Mehren, MD · Fox Chase Cancer Center

  • Vivien H.C. Bramwell, MB, BS, PhD, FRCP · Tom Baker Cancer Centre - Calgary

  • Karen H. Albritton, MD · Dana-Farber Cancer Institute

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2007-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00104949 on ClinicalTrials.gov